A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2001
11/21/2001	CN1075069C Synthesis of 3-[4-(2-aminoethoxy)-benzoyl)-2-aryl-6-hydroxybenzo(b) thiophenes
11/21/2001	CN1075064C New benzoxazinedione derivatives, and producing process thereof and use
11/21/2001	CN1075063C Asymmetric synthesis of benzoxazinones compound
11/21/2001	CN1074933C Anti-stress, anti-impairment and anti-aging medicine and process for manufacturing thereof
11/21/2001	CN1074928C Medicine for curing hemiplegia and its preparing process
11/21/2001	CN1074917C Stable carotenoid emulsions adapted for parenteral administration
11/20/2001	US6320074 In vivo modulation of lipid metabolism, skin-related processes, autoimmune diseases, fatty acid metabolism, malignant cell development, premalignant lesions, or programmed cell death
11/20/2001	US6320054 Thiazole derivatives
11/20/2001	US6320047 Substituted aryl or heteroarylamides having retinoid-like biological activity
11/20/2001	US6320036 GbpA
11/20/2001	US6320022 Adrenomedullin peptides
11/20/2001	US6319939 Retinoic acid mimetic anlides
11/20/2001	US6319930 Substituted dimeric compounds
11/20/2001	US6319924 For therapy of deleterious mental states
11/20/2001	US6319922 Propanoic acid derivatives
11/20/2001	US6319920 Muscarinic receptor antagonist used in gastrointestinal, genitourinary tract, respiratory tract, cardiovascular system, central nervous system disorders and in anesthesiology and ophthalmology
11/20/2001	US6319917 Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
11/20/2001	US6319910 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
11/20/2001	US6319907 Administering latency associated peptide, or a peptide analogue that is capable of maintaining transforming growth factor .beta. in latent state
11/20/2001	US6319906 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
11/20/2001	US6319900 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
11/20/2001	US6319896 Adding aqueous solution of charged polymer to solution of purified protein to reduce intermolecular or intramolecular interactions between the positively and negatively charged domains whereby solubility of protein is increased
11/20/2001	US6319703 Recombinant virus vectors
11/20/2001	US6319689 Nucleotide sequence which code aspartic protease; for treatment of alzheimer's disease, cancer; for hormone processing
11/20/2001	US6319688 Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
11/20/2001	US6319686 Nucleotide sequences coding binding protein; for use as diagnostic, drug design and therapeutic tools
11/20/2001	US6319513 Oral liquid mucoadhesive compounds
11/20/2001	US6319510 Pad to be installed on gum comprising nonporous layer, adjacent layer retaining medication capable of being liquefied by saliva, semipermeable layer covering second layer and sealed to first layer to form pocket enclosing second layer
11/20/2001	CA2257431C Fast-dissolving galanthamine hydrobromide tablet
11/20/2001	CA2176668C Heterocyclic spiro compounds, process for preparing the same and pharmaceutical compositions containing them
11/20/2001	CA2174854C Quinazoline derivative
11/19/2001	CA2308994A1 Neuroprotective compounds
11/18/2001	CA2722134A1 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
11/15/2001	WO2001086002A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/15/2001	WO2001085993A2 Method for detecting growth hormone variations in humans, the variations and their uses
11/15/2001	WO2001085984A1 Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
11/15/2001	WO2001085980A2 Enzymatic assays for screening anti-cancer agents
11/15/2001	WO2001085960A1 Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy
11/15/2001	WO2001085956A2 Lipid metabolism enzymes
11/15/2001	WO2001085953A1 Sphingosine kinase and uses thereof
11/15/2001	WO2001085942A2 Cytoskeleton-associated proteins
11/15/2001	WO2001085941A2 Myc targets
11/15/2001	WO2001085938A1 Modified es cells and es cell-specific gene
11/15/2001	WO2001085937A2 Regulator of g protein signalling (rgs8)
11/15/2001	WO2001085797A1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
11/15/2001	WO2001085790A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
11/15/2001	WO2001085785A2 Ph domain-interacting protein
11/15/2001	WO2001085779A2 Protein complexes and assays for screening anti-cancer agents
11/15/2001	WO2001085763A2 Chimeric peptide immunogens their preparation and use
11/15/2001	WO2001085762A2 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	WO2001085727A1 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
11/15/2001	WO2001085726A1 Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
11/15/2001	WO2001085725A1 Piperazine and piperidine compounds
11/15/2001	WO2001085722A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
11/15/2001	WO2001085721A1 N-sulfonyl hydroxamic acid derivatives as inhibitors of cd 23
11/15/2001	WO2001085719A1 Ortho-substituted anthranilic acid amides and their use as medicaments
11/15/2001	WO2001085707A1 Para-amine substituted phenylamide glucokinase activators
11/15/2001	WO2001085706A1 Substituted phenylacetamides and their use as glucokinase activators
11/15/2001	WO2001085702A1 (e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-(3r,5s)-dihydroxyhept-6-enoic acid.
11/15/2001	WO2001085701A1 5-ht7 receptor antagonists
11/15/2001	WO2001085699A2 Prodrugs of hiv replication inhibiting pyrimidines
11/15/2001	WO2001085694A2 Substituted diamide derivatives useful as motilin antagonists
11/15/2001	WO2001085693A1 N-acyltetrahydroisoquinoline derivatives
11/15/2001	WO2001085686A2 Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes
11/15/2001	WO2001085685A1 Heterocyclic inhibitors of glycogen synthase kinase gsk-3
11/15/2001	WO2001085677A1 Amino acid derivatives and their use as medicines
11/15/2001	WO2001085671A2 Anthranyl amides and their use as medicaments
11/15/2001	WO2001085668A1 Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
11/15/2001	WO2001085664A2 Compounds and methods for regulating bacterial growth and pathogenesis
11/15/2001	WO2001085621A1 High functional water containing titanium and method and apparatus for producing the same
11/15/2001	WO2001085257A2 Opioid antagonist compositions and dosage forms
11/15/2001	WO2001085256A2 Critical illness neuropathy
11/15/2001	WO2001085206A2 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
11/15/2001	WO2001085204A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	WO2001085203A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	WO2001085199A1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR
11/15/2001	WO2001085198A1 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII
11/15/2001	WO2001085196A2 Cxcr4 antagonist treatment of hematopoietic cells
11/15/2001	WO2001085193A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
11/15/2001	WO2001085191A1 Hyaluronidase activity and allergenic cell activity inhibitor
11/15/2001	WO2001085171A1 Local anesthetic methods and kits
11/15/2001	WO2001085169A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085168A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
11/15/2001	WO2001085166A1 Methods for inhibiting proliferation and inducing apoptosis in cancer cells
11/15/2001	WO2001085155A1 Method and compositions for inhibiting arteriosclerosis
11/15/2001	WO2001085152A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085150A2 Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
11/15/2001	WO2001085147A2 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF
11/15/2001	WO2001085146A1 Pharmaceutical compounds for treating copd
11/15/2001	WO2001085145A2 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
11/15/2001	WO2001085116A2 Synergistic antiplaque/antigingivitis oral composition
11/15/2001	WO2001085096A2 Mast cell regulation
11/15/2001	WO2001085093A2 Compounds and methods for modulating cerebral amyloid angiopathy
11/15/2001	WO2001076627A8 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
11/15/2001	WO2001060375A8 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration
11/15/2001	WO2001047498A3 Hydrogel-driven layered drug dosage form comprising sertraline
11/15/2001	WO2001040185B1 Compounds, compositions, and methods for stimulating neuronal growth and elongation
11/15/2001	WO2001034601A3 Imidazopyridine derivatives as phosphodiesterase vii inhibitors
11/15/2001	WO2001017963A3 Aminoalkoxy carbazoles and their use as 5-ht ligands
11/15/2001	WO2001016136B1 Tricyclic inhibitors of poly(adp-ribose) polymerases

1 ... 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 ... 1564